Yiling Group

Shijiazhuang Yiling Pharmaceutical is a prominent Chinese pharmaceutical company that integrates research, development, production, and marketing of modern Traditional Chinese Medicine (TCM), chemical drugs, and biologics. Founded in 1992 by Academician Wu Yiling, the company operates based on the "Collateral Disease Theory" (Luobing Theory), a unique academic framework used to develop innovative treatments for cardiovascular, cerebrovascular, and respiratory diseases. Its flagship product, Lianhua Qingwen, is widely recognized globally for its use in treating influenza and COVID-19. Yiling Pharmaceutical maintains a strong R&D focus, expanding its pipeline into oncology and metabolic diseases while operating large-scale GMP-certified manufacturing facilities. The company is a key player in the modernization of TCM and its integration into evidence-based clinical practice.